Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CpG-STAT3 siRNA + Radiation in Relapsed/Refractory B-Cell NHL
NCT04995536Phase 1Withdrawn
- Sponsor
- City of Hope
- Start
- Jul 2021
- Primary completion
- Jan 2024
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
01
Overview
Phase 1, open-label, single-arm trial of CpG-STAT3 siRNA in B-cell non-Hodgkin lymphoma, sponsored by City of Hope. Primary endpoints: Incidence of adverse events up to 6 months and Dose Limiting Toxicity up to 56 days. Planned start Jul 2021; status: withdrawn.
02
Drugs
CpG-STAT3 siRNA
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04995536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04995536.